Syncom Formulations India Ltd vs Wockhardt Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Syncom Formulations (India) Ltd is ₹ 13.73 as of 30 Apr 15:30 . The P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.7 on March 2021 to 6.7 on March 2021 . This represents a CAGR of 0.00% over 1 years The Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 3800 crore on March 2022 to ₹ 4590 crore on March 2021 . This represents a CAGR of 3.85% over 5 years The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The revenue of Wockhardt Ltd for the Dec '25 is ₹ 913 crore as compare to the Sep '25 revenue of ₹ 803 crore. This represent the growth of 13.7% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The ebitda of Wockhardt Ltd for the Dec '25 is ₹ 192 crore as compare to the Sep '25 ebitda of ₹ 199 crore. This represent the decline of -3.52% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The net profit of Wockhardt Ltd changed from ₹ -16 crore to ₹ 61 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

About Wockhardt Ltd

Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

FAQs for the comparison of Syncom Formulations (India) Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Syncom Formulations (India) Ltd or Wockhardt Ltd?

Market cap of Syncom Formulations (India) Ltd is 1,290 Cr while Market cap of Wockhardt Ltd is 22,661 Cr

What are the key factors driving the stock performance of Syncom Formulations (India) Ltd and Wockhardt Ltd?

The stock performance of Syncom Formulations (India) Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Syncom Formulations (India) Ltd and Wockhardt Ltd?

As of May 4, 2026, the Syncom Formulations (India) Ltd stock price is INR ₹13.73. On the other hand, Wockhardt Ltd stock price is INR ₹1394.6.

How do dividend payouts of Syncom Formulations (India) Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Syncom Formulations (India) Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.